Table II.
EGFR immunostaining in the surgically resected cancers and the far advanced cancers obtained at autopsy.
| No. of cases (%)
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Membranous EGFR reactivity
|
Cytoplasmic EGFR reactivity
|
|||||||
| Total | 0 | 1+ | 2+ | 3+ | 0 | 1+ | 2+ | |
| Surgically resected cancers | 44 | 24 (55) | 7 (16) | 12 (27) | 1 (2) | 22 (50) | 12 (27) | 10 (23) |
| Far advanced cancers | 40 | 6 (15) | 15 (38) | 7 (18) | 12 (30) | 4 (10) | 23 (58) | 13 (33) |
| Primary cancersa | 20 | 3 (15) | 9 (45) | 3 (15) | 5 (25) | 2 (10) | 13 (65) | 5 (25) |
| Hepatic metastasesa | 20 | 3 (15) | 6 (30) | 4 (20) | 7 (35) | 2 (10) | 10 (50) | 8 (40) |
a
No significant difference between membranous and cytoplasmic EGFR reactivity.